CA2319782A1 - Complexes proteiques de retinoblastome et proteines interagissant avec le retinoblastome - Google Patents

Complexes proteiques de retinoblastome et proteines interagissant avec le retinoblastome Download PDF

Info

Publication number
CA2319782A1
CA2319782A1 CA002319782A CA2319782A CA2319782A1 CA 2319782 A1 CA2319782 A1 CA 2319782A1 CA 002319782 A CA002319782 A CA 002319782A CA 2319782 A CA2319782 A CA 2319782A CA 2319782 A1 CA2319782 A1 CA 2319782A1
Authority
CA
Canada
Prior art keywords
protein
complex
derivative
glut1
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002319782A
Other languages
English (en)
Inventor
Vincent Peter Schulz
Meijia Yang
Krishnan Nandabalan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CuraGen Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2319782A1 publication Critical patent/CA2319782A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4736—Retinoblastoma protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des complexes de la protéine du rétinoblastome (RB) avec des protéines identifiées comme interagissant avec RB par un système amélioré de criblage à deux hybrides de levures modifiés. Les protéines identifiées comme devant interagir avec RB sont RN-tre, CAS, IP-30, L6, IK, LDH-B, Nlk1(Nek 2), cyclophiline A, Zap 3, CD24*, Set*, GluT1* et 115392*. Ainsi, l'invention présente concerne des complexes de RB et de RN-tre, CAS, IP-30, L6, IK, LDH-B, Nlk1(Nek 2), la cyclophiline A, Zap 3, CD24*, Set*, GluT1* et 115392* ainsi que des dérivés, fragments et analogues desdits composés. L'invention concerne également les gènes et protéines CD24*, Set*, GluT1* et 115392* ainsi que des dérivés, fragments et analogues de ces composés. L'invention a également trait à des techniques de criblage de complexes visant à améliorer l'efficacité du traitement et/ou de la prévention de certaines maladies et troubles, notamment de pathologies hyperprolifératives dont le cancer, les maladies neurodégénératives et les maladies virales.
CA002319782A 1998-02-12 1999-02-12 Complexes proteiques de retinoblastome et proteines interagissant avec le retinoblastome Abandoned CA2319782A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7455998P 1998-02-12 1998-02-12
US60/074,559 1998-02-12
US24896099A 1999-02-11 1999-02-11
US09/248,960 1999-02-11
PCT/US1999/003072 WO1999041376A2 (fr) 1998-02-12 1999-02-12 Complexes proteiques de retinoblastome et proteines interagissant avec le retinoblastome

Publications (1)

Publication Number Publication Date
CA2319782A1 true CA2319782A1 (fr) 1999-08-19

Family

ID=26755794

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002319782A Abandoned CA2319782A1 (fr) 1998-02-12 1999-02-12 Complexes proteiques de retinoblastome et proteines interagissant avec le retinoblastome

Country Status (4)

Country Link
EP (1) EP1054969A2 (fr)
JP (1) JP2002503466A (fr)
CA (1) CA2319782A1 (fr)
WO (1) WO1999041376A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476193B1 (en) 1998-10-06 2002-11-05 Curagen Corporation NLK1 protein and NLK1 protein complexes
AU2003274911A1 (en) * 2002-08-07 2004-02-25 Exelixis, Inc. Mrbs as modifiers of the rb pathway and methods of use
EP1578945A4 (fr) * 2002-11-25 2006-09-27 Exelixis Inc Cct6 utilises comme modificateurs de la voie rb, et procedes d'utilisation correspondants
EP2087114B1 (fr) 2006-11-13 2013-05-29 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Procédés de traitement d'un cancer à l'aide de molécules d'arnic dirigées contre cd24

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071715A (en) * 1993-08-12 2000-06-06 Board Of Regents, The University Of Texas System Nucleic acids encoding novel proteins which bind to retinoblastoma protein
EP0685493A1 (fr) * 1994-06-01 1995-12-06 CANJI, Inc. Protéines de fusion suppresseurs de tumeurs
AU723660B2 (en) * 1996-11-15 2000-08-31 Canji, Inc. Tissue specific expression of retinoblastoma protein

Also Published As

Publication number Publication date
WO1999041376A9 (fr) 2001-02-01
WO1999041376A8 (fr) 2000-10-12
JP2002503466A (ja) 2002-02-05
WO1999041376A3 (fr) 2000-02-10
WO1999041376A2 (fr) 1999-08-19
EP1054969A2 (fr) 2000-11-29

Similar Documents

Publication Publication Date Title
US6627405B1 (en) 53BP2 complexes
AU4869399A (en) Interaction of human beta amyloid precursor protein (beta-app) with human lon-protease like protein (hslon)
AU778692B2 (en) NLK1 -interacting proteins
AU761651B2 (en) CDK2 protein and CDK2 protein complexes
JP2002510490A (ja) Ｌｙｓｔタンパク質複合体およびｌｙｓｔ相互作用タンパク質
EP1177286A1 (fr) Proteine capable d'interaction avec un polypeptide mdm et procedes d'utilisation
AU770000B2 (en) Hermansky pudlak syndrome protein-interacting proteins and methods of use thereof
CA2319782A1 (fr) Complexes proteiques de retinoblastome et proteines interagissant avec le retinoblastome
AU4690499A (en) Interaction of p27(kip1) with fkbp-12
AU3291799A (en) Retinoblastoma protein complexes and retinoblastoma interacting proteins
CA2349839C (fr) Ucp5
WO2002102987A2 (fr) Methodes et compositions basees sur des interactions proteiques avec mastermind

Legal Events

Date Code Title Description
FZDE Dead